Janssen Sciences Ireland UC announced it and other Janssen affiliates will present 13 research abstracts, covering ongoing work into potential treatments for the hepatitis B virus (HBV) and potential and approved ones for hepatitis C (HCV), at the International Liver Congress of the European Association for the Study of the Liver (EASL 2016), set for April 13–17 in Barcelona, Spain.
“Despite recent advances, the global impact of viral hepatitis remains far reaching with significant unmet needs yet to be addressed. We have come a long way in developing cures for hepatitis C, but further innovation is needed to deliver one treatment suitable for all patient types,” Lawrence M. Blatt, PhD, Global Therapeutic Area head, Infectious Diseases and Vaccines for Janssen Research & Development, said in a press release. “Chronic hepatitis B is a potentially fatal liver disease that requires life-long treatment. There remains no known cure which represents an unmet medical need and we are excited by the opportunity to fully leverage our expertise in this critical disease area in order to bring potentially new treatments to patients.”